Re: Nothing to Say???
I don't think it can be argued that there is a positive trend towards cognitive improvement based on today's presentation, in particular in the completer population which IMO is going to eventually be the way new Alzheimer's drugs are judged, at least in moderate to severe cases. More placebo patients dropped out than did the 20ug patients. That is evidence as how hard it is to run such a trial.
Results are well above placebo in the completer population across the board at any time interval shown in both SIB and ADCS measurements, some even within the .05 level of significance. 5 weeks in seemed to show the biggest improvements in the study with lesser improvements at week 9 and then increasing again as week 13 approached. This is similar to the data we saw of compassionate use patient number 3...giving hope that a longer study can sustain higher scores well out past the 3 month mark.
Long story short, 20ug of bryostatin will be the dosage used moving forward. Showed a clear benefit and was well tolerated. Showed statistically significant results at first measurements at week 5. Can/will probably be tweaked further and studied for a longer period of time. Trend line was moving up nicely at week 13 while it was falling for placebo, making statistical significance even more likely as length of study increases.
Would love to see the individual results of the 4 patients who were not on any Alz drug in combo with bryostatin. Would love to see more specific trials run for genetic issues. That's simply not where the company currently is. Company needs to give an operational update IMO but not for me to judge. Just my take.